Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy

Abstract Membranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical features but different treatment strategies and prognoses. M-type phospholipase A2 receptor (PLA2R) is considered as a specific marker of membran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng Wu, Yiding Zhang, Wen Cui, Yijun Dong, Yingyang Geng, Changhao Liu, Zemeng Li, Yandong Xie, Xiaojing Cai, Jin Shang, Jing Xiao, Zhanzheng Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1136edcd8ec746dab3179c01bccfa05c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1136edcd8ec746dab3179c01bccfa05c
record_format	dspace
spelling	oai:doaj.org-article:1136edcd8ec746dab3179c01bccfa05c2021-12-02T17:19:17ZDevelopment and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy10.1038/s41598-021-97517-82045-2322https://doaj.org/article/1136edcd8ec746dab3179c01bccfa05c2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97517-8https://doaj.org/toc/2045-2322Abstract Membranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical features but different treatment strategies and prognoses. M-type phospholipase A2 receptor (PLA2R) is considered as a specific marker of membranous nephropathy. However, its sensitivity is only about 70%. Therefore, there is a lack of effective and noninvasive tools to distinguish PLA2R-negative MN and MCD patients without renal biopsy. A total 949 patients who were pathologically diagnosed as idiopathic MN or MCD were enrolled in this study, including 805 idiopathic MN and 144 MCD. Based on the basic information and laboratory examination of 200 PLA2R-negative MN and 144 MCD, we used a univariate and multivariate logistic regression to select the relevant variables and develop a discrimination model. A novel model including age, albumin, urea, high density lipoprotein, C3 levels and red blood cell count was established for PLA2R-negative MN and MCD. The discrimination model has great differential capability (with an AUC of 0.904 in training group and an AUC of 0.886 in test group) and calibration capability. When testing in all 949 patients, our model also showed good discrimination ability for all idiopathic MN and MCD.Feng WuYiding ZhangWen CuiYijun DongYingyang GengChanghao LiuZemeng LiYandong XieXiaojing CaiJin ShangJing XiaoZhanzheng ZhaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Feng Wu Yiding Zhang Wen Cui Yijun Dong Yingyang Geng Changhao Liu Zemeng Li Yandong Xie Xiaojing Cai Jin Shang Jing Xiao Zhanzheng Zhao Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
description	Abstract Membranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical features but different treatment strategies and prognoses. M-type phospholipase A2 receptor (PLA2R) is considered as a specific marker of membranous nephropathy. However, its sensitivity is only about 70%. Therefore, there is a lack of effective and noninvasive tools to distinguish PLA2R-negative MN and MCD patients without renal biopsy. A total 949 patients who were pathologically diagnosed as idiopathic MN or MCD were enrolled in this study, including 805 idiopathic MN and 144 MCD. Based on the basic information and laboratory examination of 200 PLA2R-negative MN and 144 MCD, we used a univariate and multivariate logistic regression to select the relevant variables and develop a discrimination model. A novel model including age, albumin, urea, high density lipoprotein, C3 levels and red blood cell count was established for PLA2R-negative MN and MCD. The discrimination model has great differential capability (with an AUC of 0.904 in training group and an AUC of 0.886 in test group) and calibration capability. When testing in all 949 patients, our model also showed good discrimination ability for all idiopathic MN and MCD.
format	article
author	Feng Wu Yiding Zhang Wen Cui Yijun Dong Yingyang Geng Changhao Liu Zemeng Li Yandong Xie Xiaojing Cai Jin Shang Jing Xiao Zhanzheng Zhao
author_facet	Feng Wu Yiding Zhang Wen Cui Yijun Dong Yingyang Geng Changhao Liu Zemeng Li Yandong Xie Xiaojing Cai Jin Shang Jing Xiao Zhanzheng Zhao
author_sort	Feng Wu
title	Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
title_short	Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
title_full	Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
title_fullStr	Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
title_full_unstemmed	Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
title_sort	development and validation of a discrimination model between primary pla2r-negative membranous nephropathy and minimal change disease confirmed by renal biopsy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1136edcd8ec746dab3179c01bccfa05c
work_keys_str_mv	AT fengwu developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT yidingzhang developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT wencui developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT yijundong developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT yingyanggeng developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT changhaoliu developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT zemengli developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT yandongxie developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT xiaojingcai developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT jinshang developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT jingxiao developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy AT zhanzhengzhao developmentandvalidationofadiscriminationmodelbetweenprimarypla2rnegativemembranousnephropathyandminimalchangediseaseconfirmedbyrenalbiopsy
_version_	1718381010378293248

Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy

Ejemplares similares